The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Q2 FY25 Total Income was at Rs. 85.4 crore
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Subscribe To Our Newsletter & Stay Updated